Saliva-first Opportunity Position Abogen as a pioneer in saliva-based research tools and diagnostics to open conversations with biotechnology firms, contract research organizations, and diagnostic labs that wish to reduce invasiveness, improve patient comfort, and lower operational costs associated with blood collection.

Vaccine Collaboration Potential Leverage Abogen’s mRNA vaccine development activity to pursue partnerships with vaccine manufacturers, public health organizations, and contract development and manufacturing organizations (CDMOs) for joint programs in Covid-19, dengue, TB, meningitis, and other infectious diseases.

Strategic Funding Signal Highlight the substantial Series C financing as an indicator of strong growth runway and investor confidence to engage potential strategic investors, pharma companies, and international research partners seeking scale, credibility, and access to capital for collaborative programs.

Bioinformatics and Data Enablement Offer integrated data and analytics collaborations around saliva-based assays, leveraging Abogen’s tech stack and validation capabilities to co-develop serological and genetic diagnostic workflows for biotech startups and diagnostic developers.

Global Collaboration Network Tap into Abogen’s existing partnerships with CanSino, Walvax, and developers of inhalable vaccines to propose multi-country trials, technology licensing, or co-development deals that expand geographic reach and diversify product pipelines for both parties.